홈/JNJ

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze JNJ in workspace
JNJNYSE/health care

Johnson & Johnson

$257.77Up+0,79 (+0,31%)
Research reviewed: 2026년 7월 12일 AM 12:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Johnson & Johnson operates in Pharmaceuticals within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Eröffnung
257,95
Hoch
259,51
Tief
256,15
Marktkapitalisierung
620,51 Mrd.
KGV
29.87
52-Wochen-Hoch
--
Dividende
2.090%
Quartalsdividende
--

3-month price context

최근 3개월 추세를 통해 전체 리서치 워크스페이스로 가기 전 단기 구조를 빠르게 파악할 수 있습니다.

Investment thesis

Base case
Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products. The base case remains conditional on talc litigation staying manageable.
Bull case
Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products. Higher procedure volumes and adoption of newer cardiovascular, surgery, orthopaedics, and vision technologies can support MedTech growth. Regulatory approvals, label expansions, and clinical readouts across medicine and MedTech can create additional durable revenue streams.
Bear case
Pending talc claims create uncertain legal costs, potential judgments, and reputational exposure that may persist despite defense and resolution efforts. Biosimilar or generic competition, government price negotiations, and payer pressure can reduce sales and margins for key medicines. Pipeline assets and medical devices may fail trials, face approval delays, encounter safety findings, or fall short of commercial adoption expectations.
Thesis invalidation
Reassess the thesis if pending talc claims create uncertain legal costs, potential judgments, and reputational exposure that may persist despite defense and resolution efforts.

Key catalysts

  • Innovative Medicine portfolio

    Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products.

  • MedTech procedure growth

    Higher procedure volumes and adoption of newer cardiovascular, surgery, orthopaedics, and vision technologies can support MedTech growth.

  • Pipeline and indication expansion

    Regulatory approvals, label expansions, and clinical readouts across medicine and MedTech can create additional durable revenue streams.

Principal risks

  • Talc litigation

    Pending talc claims create uncertain legal costs, potential judgments, and reputational exposure that may persist despite defense and resolution efforts.

  • Exclusivity and pricing pressure

    Biosimilar or generic competition, government price negotiations, and payer pressure can reduce sales and margins for key medicines.

  • Clinical and regulatory execution

    Pipeline assets and medical devices may fail trials, face approval delays, encounter safety findings, or fall short of commercial adoption expectations.

Latest earnings research

Q1 FY2026

Johnson & Johnson reported results for its fiscal first quarter ended March 29, 2026, with contributions from Innovative Medicine and MedTech and an outlook centered on portfolio growth, pipeline execution, and operational investment.

Valuation interpretation

  • Valuation should separate the growth and patent profiles of Innovative Medicine from the procedure-driven economics of MedTech.
  • A durability premium depends on pipeline replacement of mature products and should be tempered by litigation and regulatory uncertainty.

Peer research

LLYMRKNVO

Recent news

Zacks · vor 4 Stunden

Is Johnson & Johnson Stock Poised for New Highs as Q2 Results Approach?

MT Newswires · vor 5 Stunden

Update: Nasdaq Snaps 3-Day Winning Streak as Oil Jumps Amid US-Iran Tensions

24/7 Wall St. · vor 8 Stunden

How Much of Your Social Security Will You Actually Keep After Taxes?

MT Newswires · vor 8 Stunden

Equities Fall Intraday, Oil Soars as Trump Reinstates Iranian Shipping Blockade in Hormuz

Zacks · vor 9 Stunden

Can LQDA's Yutrepia Drive Growth in the Competitive PAH Market?

24/7 Wall St. · vor 10 Stunden

JNJ Vs. KO: Which Dividend Stock Is The Better Buy?

Data and research sources

Research updated: 2026년 7월 12일 AM 12:00 UTC
3 verified sources
Johnson & Johnson 2026 First-Quarter ResultsJohnson & Johnson · earningsVerified

Fetched: 2026. 7. 12. AM 12시 0분 0초 UTC

Published: 2026. 4. 14. AM 10:45:00

Open original source
Johnson & Johnson Investor RelationsJohnson & Johnson · companyVerified

Fetched: 2026. 7. 12. AM 12시 0분 0초 UTC

Open original source
Johnson & Johnson Form 10-Q for the fiscal quarter ended March 29, 2026U.S. Securities and Exchange Commission · filingVerified

Fetched: 2026. 7. 12. AM 12시 0분 0초 UTC

Published: 2026. 4. 22. AM 12:00:00

Open original source

Continue in the research workspace

Keep JNJ in context, run a multi-agent analysis, and monitor thesis changes.

Analyze JNJ free

전체 리서치 시스템 살펴보기

각 단계는 고유한 역할을 수행하고 다음 단계가 확인할 수 있는 결과를 남깁니다.

리서치 방법론시장 보고서 읽기종목 둘러보기

Continue researching this stock

시장 분석가

시장 분석가는 핵심 리서치 안에서 관찰 단계에 집중해 다음 판단의 전제를 정리하는 역할입니다.

기본면 분석가

기본면 분석가는 핵심 리서치 안에서 관찰 단계에 집중해 다음 판단의 전제를 정리하는 역할입니다.

뉴스 분석가

뉴스 분석가는 핵심 리서치 안에서 관찰 단계에 집중해 다음 판단의 전제를 정리하는 역할입니다.

리스크 매니저

리스크 매니저는 리스크와 모니터링 안에서 모니터링 단계에 집중해 다음 판단의 전제를 정리하는 역할입니다.